Does Renal Denervation a Reasonable Treatment Option in Hemodialysis-Dependent Patient with Resistant Hypertension? A Narrative Review
Purpose of Review This narrative review aims to assess the pathophysiology, diagnosis, and treatment of resistant hypertension (RH) in end-stage kidney disease (ESKD) patients on dialysis, with a specific focus on the effect of renal denervation (RDN) on short-term and long-term blood pressure (BP) control. Additionally, we share our experience with the use of RDN in an amyloidotic patient undergoing hemodialysis with RH. Recent Findings High BP, an important modifiable cardiovascular risk factor, is often observed in patients in ESKD, despite the administration of multiple antihypertensive medications. However, in clinical practice, it remains challenging to identify RH patients on dialysis treatment because of the absence of specific definition for RH in this context. Moreover, the use of invasive approaches, such as RDN, to treat RH is limited by the exclusion of patients with reduced renal function (eGFR < 45 mL/min/1.73 m3) in the clinical trials. Nevertheless, recent studies have reported encouraging results regarding the effectiveness of RDN in stage 3 and 4 chronic kidney disease (CKD) and ESKD patients on dialysis, with reductions in BP of nearly up to 10 mmhg. Summary Although multiple underlying pathophysiological mechanisms contribute to RH, the overactivation of the sympathetic nervous system in ESKD patients on dialysis plays a crucial role. The diagnosis of RH requires both confirmation of adherence to antihypertensive therapy and the presence of uncontrolled BP values by ambulatory BP monitoring or home BP monitoring. Treatment involves a combination of nonpharmacological approaches (such as dry weight reduction, sodium restriction, dialysate sodium concentration reduction, and exercise) and pharmacological treatments. A promising approach for managing of RH is based on catheter-based RDN, through radiofrequency, ultrasound, or alcohol infusion, directly targeting on sympathetic overactivity..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Current hypertension reports - 25(2023), 11 vom: 06. Sept., Seite 353-363 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mazza, Alberto [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Blood pressure |
|---|
| Anmerkungen: |
© The Author(s) 2023. corrected publication 2023 |
|---|
| doi: |
10.1007/s11906-023-01264-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053511239 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053511239 | ||
| 003 | DE-627 | ||
| 005 | 20231025064652.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231025s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11906-023-01264-2 |2 doi | |
| 035 | |a (DE-627)SPR053511239 | ||
| 035 | |a (SPR)s11906-023-01264-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mazza, Alberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Does Renal Denervation a Reasonable Treatment Option in Hemodialysis-Dependent Patient with Resistant Hypertension? A Narrative Review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023. corrected publication 2023 | ||
| 520 | |a Purpose of Review This narrative review aims to assess the pathophysiology, diagnosis, and treatment of resistant hypertension (RH) in end-stage kidney disease (ESKD) patients on dialysis, with a specific focus on the effect of renal denervation (RDN) on short-term and long-term blood pressure (BP) control. Additionally, we share our experience with the use of RDN in an amyloidotic patient undergoing hemodialysis with RH. Recent Findings High BP, an important modifiable cardiovascular risk factor, is often observed in patients in ESKD, despite the administration of multiple antihypertensive medications. However, in clinical practice, it remains challenging to identify RH patients on dialysis treatment because of the absence of specific definition for RH in this context. Moreover, the use of invasive approaches, such as RDN, to treat RH is limited by the exclusion of patients with reduced renal function (eGFR < 45 mL/min/1.73 m3) in the clinical trials. Nevertheless, recent studies have reported encouraging results regarding the effectiveness of RDN in stage 3 and 4 chronic kidney disease (CKD) and ESKD patients on dialysis, with reductions in BP of nearly up to 10 mmhg. Summary Although multiple underlying pathophysiological mechanisms contribute to RH, the overactivation of the sympathetic nervous system in ESKD patients on dialysis plays a crucial role. The diagnosis of RH requires both confirmation of adherence to antihypertensive therapy and the presence of uncontrolled BP values by ambulatory BP monitoring or home BP monitoring. Treatment involves a combination of nonpharmacological approaches (such as dry weight reduction, sodium restriction, dialysate sodium concentration reduction, and exercise) and pharmacological treatments. A promising approach for managing of RH is based on catheter-based RDN, through radiofrequency, ultrasound, or alcohol infusion, directly targeting on sympathetic overactivity. | ||
| 650 | 4 | |a Nephrectomy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Renal failure |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ultrasound |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Renin-angiotensin system inhibitors |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a End-stage kidney disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Radiofrequency ablation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Sympathetic overactivity |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Blood pressure |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Dell’Avvocata, Fabio |4 aut | |
| 700 | 1 | |a Torin, Gioia |4 aut | |
| 700 | 1 | |a Bulighin, Francesca |4 aut | |
| 700 | 1 | |a Battaglia, Yuri |0 (orcid)0000-0003-3947-1814 |4 aut | |
| 700 | 1 | |a Fiorini, Fulvio |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current hypertension reports |d Philadelphia, Pa. : Current Science Inc., 1999 |g 25(2023), 11 vom: 06. Sept., Seite 353-363 |w (DE-627)SPR022945059 |w (DE-600)2094165-1 |x 1534-3111 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:11 |g day:06 |g month:09 |g pages:353-363 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11906-023-01264-2 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 11 |b 06 |c 09 |h 353-363 | ||